Waddlia chondrophila is an emerging cause of miscarriage in bovines and humans. Given the strict intracellular growth of this Chlamydia-like organism, its antibiotic susceptibility was tested by amoebal coculture, cell culture, and real-time PCR. W. chondrophila was susceptible to doxycycline and azithromycin but resistant to ␤-lactams and fluoroquinolones.
29213 and Escherichia coli strain ATCC 25922 were determined according to the procedure recommended by the Clinical and Laboratory Standards Institute (6) . The control strains exhibited the expected MICs.
To assess the growth of W. chondrophila in amoebal cells, we used a specific quantitative real-time TaqMan PCR. DNA was extracted with the QIAamp DNA kit (Qiagen, Hilden, Germany). PCRs were performed in a final volume of 20 l including 10 l of iTaq supermix (Bio-Rad, Rheinach, Switzerland), 200 nM forward primer (WadF3, 5Ј-CAGTCGAGAATCTTTCGCAAT-3Ј), 200 nM reverse primer (WadR3, 5Ј-CAAGGTACGCTCAA ATCCAG-3Ј), 100 nM probe (WadS, 5Ј-JOE-TGAATGAAGA AGGCCCTTGGGTCGT-BHQ-3Ј), 4.5 l of water, and 5 l of DNA. Cycling conditions were 2 min at 50°C, 10 min at 95°C, and 45 cycles of 15 s at 95°C and 1 min at 60°C. Amplification and detection of PCR products were performed with the ABI Prism 7000 (Applied Biosystems, Rotkreuz, Switzerland). The variability of this real-time PCR is about 0.5 log. Susceptibility was thus defined as a reduction in the number of DNA copies of more than 0.5 log in the presence of a given antibiotic concentration compared to the control growth curve without antibiotic.
W. chondrophila strains ATCC VR-1470 and 2032/99 exhibited doxycycline MICs of 4 g/ml (Fig. 1A ) and 1 g/ml, respectively. Both strains were susceptible to azithromycin. Strain ATCC VR-1470 growth was inhibited by 0.125 g/ml in most experiments. In additional experiments, growth was inhibited by 0.06 g/ml (Fig. 1B) . Thus, the MICs of azithromycin for this strain ranged between 0.06 and 0.125 g/ml. W. chondrophila strain 2032/99 had an azithromycin MIC of 0.06 g/ml. Both strains exhibited resistance to ␤-lactams (ampicillin, ceftriaxone), with MICs of Ն32 g/ml, and fluoroquinolones (ciprofloxacin, ofloxacin), with MICs of Ն16 g/ml (Fig.  1C , D, E, and F).
To confirm the results obtained with amoebae, we tested the antibiotic susceptibility of W. chondrophila strain VR-1470 in Vero cells. We used a procedure similar to that used for amoebae, except that infected Vero cells were suspended in RMPI medium-10% fetal calf serum and incubated at 37°C in a 5% CO 2 atmosphere. W. chondrophila was susceptible to azithromycin and doxycycline, with a MIC of 0.25 g/ml for both antibiotics. Similarly to what was observed in amoebae, W. chondrophila was resistant to fluoroquinolones (MICs of Ն16 g/ml) and ␤-lactams (MICs of Ն32 g/ml). The MIC of doxycycline was slightly higher in amoebae than in mammalian cells. This may be due to the presence of some efflux machinery in amoebae that protects these protists from chemical compounds present in water. For all other antibiotics, the MICs observed with both types of cells were similar, indicating that amoebae may represent a good alternative to mammalian cells to test the antibiotic susceptibility of strictly intracellular bac- teria such as Parachlamydia acanthamoebae that do not grow in mammalian cells (18) . The susceptibility pattern of W. chondrophila is relatively similar to that obtained for other members of the order Chlamydiales (Table 1) . Indeed, Chlamydophila pneumoniae and Chlamydia trachomatis are both susceptible to macrolides and tetracyclines (4, 8, 14, 17, 25, 27, 28) . However, unlike W. chondrophila, both of these chlamydiae are susceptible to quinolones (13, 14, 19, 20, 22) . Interestingly, P. acanthamoebae is, like W. chondrophila, resistant to fluoroquinolones (3, 18) . The resistance to fluoroquinolones was also observed for other Chlamydia-related bacteria, including Neochlamydia hartmanellae and Simkania negevensis (3) . In the latter study, quinolone resistance in these amoeba-resisting bacteria could be explained by mutations in the quinolone resistance-determining regions (QRDR) of the DNA gyrase A (GyrA)-and topoisomerase IV (ParC)-encoding genes. We thus sequenced the QRDR of both genes for the two W. chondrophila strains available to date. Both strains exhibited the same QRDR sequences. In GyrA, we observed a Ser-833Gln substitution, which is known to be associated with the resistance phenotype ( Fig. 2A) . A Val-703Ser substitution was also observed. Both substitutions were already observed in the GyrA QRDR of P. acanthamoebae (3) . In the ParC QRDR, Ser-813Ala and Glu843Asp substitutions were observed (Fig. 2B) . The latter substitution can also be observed in Streptococcus pneumoniae, conferring quinolone resistance on mutant strains (21) . The resistance of W. chondrophila to quinolones might thus be explained by the mutations present in the GyrA and ParC QRDR.
In conclusion, azithromycin and doxycycline are active in vitro against both strains of W. chondrophila whereas quinolones and ␤-lactams are not. Resistance of W. chondrophila to penicillin was already documented in BT cells (7) .
Consequently, azithromycin should be considered to treat infections due to this intracellular bacterium, given its excellent bioavailability and its documented activity against other members of the order Chlamydiales (17, 26) . Macrolides might be an especially good first choice to prevent miscarriage, given the contraindication of using doxycycline during pregnancy. Doxycycline might, of course, be an alternative agent for nonpregnant patients. In the future, it will be important to test the activity of these antibiotics against W. chondrophila in vivo.
